King of Prussia's Vertex will reduce its workforce by nine percent, as the compliance software maker pivots toward artificial intelligence. In a Securities and Exchange Commission filing, the company ...

It has been over four months since I last covered Vertex Pharmaceuticals (VRTX), where I discussed how the company was still the unquestionable leader in cystic fibrosis (CF) but was working to ...

Vertex, Inc. (NASDAQ:VERX) is included in our list of the 10 stocks insiders are buying now. As of March 27, 2026, analyst sentiment on Vertex, Inc. (NASDAQ:VERX) remains constructive, with over 50% ...

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease. Vertex ...

March 9 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Monday that its experimental drug sharply reduced a key sign of kidney damage in a late‑stage ‌trial, putting the company on ...

Rachel Williams has been an editor for nearly two decades. She has spent the last five years working on small business content to help entrepreneurs start and grow ...

It’s Friday the 13th, and investors will be hoping the software horror show ends soon. Fears that artificial intelligence products will butcher the business models of software-as-a-service companies ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Vertex executives warned that Casgevy, its ...

"Law & Order: Special Victims Unit" actor BD Wong apologized for a now-deleted racist comment he made on social media. Wong commented on the post, writing: "It appears to be a Black man," Variety and ...

The actor added several hours later, “I want to elaborate on a racist comment I posted, to clarify that I recognize & accept the responsibility for how terrible it is. It’s also wrong to try to ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy. Vertex clocked 11% growth ...